More Percheron Therapeutics Limited news
Percheron Therapeutics LimitedASX: PER

Quarterly Activities Report and Appendix 4C

Oct 19, 2026 at 8:15 PM EDT · Issued by Percheron Therapeutics Limited

Filed with ASX · Oct 19, 2026 at 8:15 PM EDT · 10 pages · English

On 6ix: 6ix.com/news/quarterly-activities-report-and-appendix-4c-122

Percheron Therapeutics Limited on 6ix

Earlier from Percheron Therapeutics

  • Photosoft & Novel Immunotherapy Collab PartnershipOct 19
  • PER: Percheron and Invion Explore Cancer Combination TherapyOct 19
  • Change of Director's Interest NoticeOct 14
  • Notice under S708AOct 14
  • Application for quotation of securities - PEROct 13

Later from Percheron Therapeutics

  • Completion of HMBD-002 Drug Product ManufactureOct 22
  • Listing Rule waiver to allow quotation of PERAQ optionsOct 29
  • FDA Clearance for Vanderbilt Health Clinical Trial in AMLNov 1
  • Prospectus - Placement options and JLM optionsNov 3
  • Update - Proposed issue of securities - PERNov 3
All Percheron Therapeutics news releases↗

Follow Percheron Therapeutics into a list and get an email when it puts out news.

Follow Percheron Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer